Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis Inc. reports developments from its oncology business, including commercial performance for the cabozantinib franchise and clinical and regulatory updates across cancer programs. The company discovers, develops and commercializes cancer medicines, with CABOMETYX® (cabozantinib) as its flagship commercial product and COMETRIQ® also part of its cabozantinib portfolio.
Recurring updates include quarterly financial results, product revenue trends, financial guidance, pipeline milestones and investor conference presentations. Exelixis also discusses zanzalintinib, an investigational oral kinase inhibitor, and a broader pipeline of small molecules and biotherapeutics targeting additional tumor types and indications.
Exelixis, Inc. (NASDAQ: EXEL) announced the enrollment of the first patient in the dose-escalation cohort of a phase 1 trial (NCT03845166) for XL092, a next-generation oral tyrosine kinase inhibitor. This trial evaluates XL092 alone and in combination with atezolizumab for patients with advanced solid tumors. Preliminary findings suggest that XL092 may promote an immune-permissive environment and have a shorter pharmacokinetic half-life compared to cabozantinib, aiding in tolerability management. The trial, initiated in February 2019, will eventually explore various cancer types.
Exelixis, Inc. (Nasdaq: EXEL) will announce its third quarter 2020 financial results on November 5, 2020, after market close. Management will host a conference call at 5:00 p.m. EST to discuss the results and provide business updates. Interested parties can access the event via the company’s website or by phone. Exelixis focuses on developing innovative therapies for difficult-to-treat cancers and has successfully brought multiple products to market. They are committed to increasing their pipeline through effective partnerships and reinvestment strategies.
Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited released new preclinical data indicating that AUR102, a selective covalent inhibitor of CDK7, shows significant anti-tumor activity across various cancer cell lines. Key findings include potent anti-proliferative activity and complete tumor regression in multiple xenograft models. AUR102 displays synergy with established chemotherapies and demonstrates complete target engagement. The data will be presented at the upcoming EORTC-NCI-AACR Symposium. Exelixis plans an Investigational New Drug filing for AUR102, enhancing its oncology pipeline.
Exelixis, Inc. (NASDAQ: EXEL) announced new data supporting the clinical development of XL092, a next-generation oral tyrosine kinase inhibitor targeting kinases involved in cancer growth. This data will be presented at the 32nd EORTC-NCI-AACR Symposium on October 24-25. The findings suggest XL092 has significant anti-tumor activity with a shorter half-life compared to cabozantinib. The ongoing phase 1 trial will also explore the combination of XL092 with atezolizumab in various solid tumors, enhancing its therapeutic potential.